ORKA
NASDAQOruka Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
Price$60.12+25.02 (+71.32%)
2026-03-042026-06-05
News · 26 weeks58-31%
2025-12-142026-06-07
Mix4190d
- Insider15(37%)
- SEC Filings14(34%)
- Other7(17%)
- Offering3(7%)
- Earnings2(5%)
Latest news
25 items- SECOruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- INSIDERSEC Form 4 filed by Director Dambkowski Carl4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 4 filed by Director Kulkarni Samarth4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 4 filed by Director Martin Christopher Nathan4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 4 filed by Director Ball Kristine M4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 4 filed by Director Fairmount Funds Management Llc4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECOruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- PRPhase 2 Data could Transform these Biotechs from Clinical Promise to Market ValidationDENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts. Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store That is why so much attention is focused on companies that are approaching pivotal readouts or are fresh off meaningful Phase 2 updates that could materially
- PROruka Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceMENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation at the 2026 Jefferies Global Healthcare Conference, taking place in New York, NY from June 2-4, 2026. Presentation DetailsDate: Wednesday, June 3rd, 2026Presentation Time: 3:45PM ET A webcast and replay of Oruka's presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations. About Oruka TherapeuticsOruka Therapeutics is de
- INSIDERDirector Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSenior Vice President, Finance Agarwal Arjun exercised 7,833 shares at a strike of $28.80 and sold $607,806 worth of shares (10,290 units at $59.07) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 16,406 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $432,935 worth of shares (7,000 units at $61.85) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- PROruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027 Post-offering cash, cash equivalents and marketable securities expected to fund Company through BLA for ORKA-001 MENLO PARK, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported first quarter 2026 financial results and provided a corporate upda
- SECSEC Form 10-Q filed by Oruka Therapeutics Inc.10-Q - Oruka Therapeutics, Inc. (0000907654) (Filer)
- PRAchieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona PharmaSEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced three senior leadership appointments. Christopher Martin has joined the Company's Board of Directors. Mark Zappia has joined as Senior Vice President, Commercial, where he will spearhead the Company's commercial function. Jim Willis has joined as Vice President of Sales and Sales Enablement, where he will lead the field force. Mr. Martin most recently served as Chief Commercia
- PRHalozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ TechnologyAgreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional targetSAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") and Oruka Therapeutics, Inc. (NASDAQ:ORKA) ("Oruka") today announced that Halozyme's wholly‑owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Oruka.Under the agreement, Oruka has licensed Halozyme's Hypercon™ technology for use with ORKA‑001, in development for psoriasis and related inflammatory diseases, and up to one additional target. Hypercon™ is an innovative microparticle technology that allows for
- INSIDERChief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $319,384 worth of shares (5,000 units at $63.88) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECOruka Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- SECSEC Form 424B5 filed by Oruka Therapeutics Inc.424B5 - Oruka Therapeutics, Inc. (0000907654) (Filer)
- PROruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public OfferingMENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (NASDAQ:ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced the pricing of its upsized underwritten public offering of 9,660,000 shares of its common stock at a price to the public of $72.50 per share. The gross proceeds to Oruka from this offering are expected to be approximately $700.4 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. In additio
- SECSEC Form 424B5 filed by Oruka Therapeutics Inc.424B5 - Oruka Therapeutics, Inc. (0000907654) (Filer)
- SECSEC Form 424B5 filed by Oruka Therapeutics Inc.424B5 - Oruka Therapeutics, Inc. (0000907654) (Filer)
- PROruka Therapeutics Announces Proposed $500 Million Underwritten Public OfferingMENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (NASDAQ:ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Oruka expects to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of its common stock at the public offering price, less underwriting discounts and co
- SECOruka Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- PROruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque PsoriasisORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term EVERLAST-A data expected in 2H 2026 Management to host a conference call today at 8:00 a.m. ET MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal ant
ORKA FAQ
5 questionsWhere does ORKA stock trade?
Oruka Therapeutics Inc. (ORKA) is listed on NASDAQ.What sector and industry is ORKA in?
Oruka Therapeutics Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about ORKA?
Oruka Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight on 2025-12-18. Recent price targets range from $2000.00 to $4900.00.What companies are similar to ORKA?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), NNNN (Anbio Biotechnology), CLDX (Celldex Therapeutics Inc.). Compare ORKA side-by-side with any of them on Quantisnow.How can I track ORKA on Quantisnow?
Quantisnow aggregates Oruka Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ORKA to receive live email and push alerts on every new disclosure.